Condition:   Acute Gout
Interventions:   Drug: ACZ885;   Drug: Triamcinolone acetonide
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified March 2010

Condition:   Bowel Preparation
Interventions:   Drug: PicoPrep;   Drug: HalfLytely
Sponsor:   Ferring Pharmaceuticals
Not yet recruiting - verified February 2010

Conditions:   Diabetic Neuropathy, Painful;   Diabetic Polyneuropathy
Interventions:   Drug: Oxycodone controlled release (CR);   Drug: Tapentadol extended release (ER)
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Grünenthal GmbH
Recruiting - verified February 2010

Condition:   Influenza
Intervention:   Drug: Peramivir
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified January 2010

Condition:   Sexual Dysfunctions, Psychological
Interventions:   Drug: Flibanserin;   Drug: Placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Diabetic Neuropathy, Painful;   Diabetic Polyneuropathy
Interventions:   Drug: tapentadol extended release (ER);   Drug: placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Grünenthal GmbH
Recruiting - verified February 2010

Condition:   Alzheimer's Disease
Intervention:   Drug: Semagacestat
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Prostatic Neoplasms
Intervention:   Other: PCA3 Assay
Sponsor:   Gen-Probe, Incorporated
Recruiting - verified March 2010

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Boceprevir (SCH 503034);   Drug: erythropoietin;   Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908)
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Condition:   Gram Positive Bacterial Infection
Intervention:   Drug: Daptomycin
Sponsor:   Cubist Pharmaceuticals
Recruiting - verified February 2010

Condition:   Degenerative Disc Disease
Interventions:   Device: Aspen Spinous Process System;   Device: Pedicle Screw Fixation
Sponsor:   Lanx, Inc.
Recruiting - verified March 2010

Condition:   Schizophrenia
Interventions:   Drug: Paliperidone PR;   Drug: Aripiprazole
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Recruiting - verified March 2010

Condition:   Coronary Artery Disease
Interventions:   Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent;   Drug: prasugrel;   Drug: placebo;   Drug: aspirin
Sponsors:   Boston Scientific Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.
Recruiting - verified February 2010

Condition:   Pain
Intervention:   Drug: oxycodone immediate release (OXYRX)
Sponsor:   Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: arbaclofen placarbil;   Drug: Placebo
Sponsor:   XenoPort, Inc.
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine + preprandial lispro insulin;   Biological: albiglutide + insulin glargine
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Gastroesophageal Reflux
Interventions:   Drug: Rabeprazole sodium capsules;   Drug: placebo;   Drug: Rabeprazole sodium capsules
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Eisai Inc.
Recruiting - verified February 2010

Conditions:   Pain;   Neuralgia, Postherpetic;   Neuralgia;   Mononeuropathies
Interventions:   Drug: JNJ-42160443;   Drug: Placebo
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010

Conditions:   Seasonal Influenza;   Cough;   Sore Throat;   Nasal Congestion;   Myalgia;   Headache;   Fatigue
Interventions:   Drug: Peramivir;   Drug: Peramivir
Sponsors:   BioCryst Pharmaceuticals;   Department of Health and Human Services
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Intervention:   Drug: Dimebon
Sponsors:   Pfizer;   Medivation, Inc.
Recruiting - verified March 2010

Condition:   Postmenopausal Osteoporosis
Interventions:   Drug: Ibandronate;   Drug: Denosumab
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Schizophrenia
Interventions:   Drug: oral risperidone;   Drug: paliperidone palmitate
Sponsor:   Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010

Conditions:   Pain, Burning;   Pain, Crushing;   Pain, Migratory;   Pain, Radiating;   Pain, Splitting
Interventions:   Drug: JNJ-42160443;   Drug: Placebo
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010

Condition:   Overactive Bladder
Interventions:   Drug: Fesoterodine;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Degenerative Disc Disease
Interventions:   Device: XL TDR;   Other: Lumbar fusion surgery
Sponsor:   NuVasive
Recruiting - verified February 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Hereditary Angioedema
Interventions:   Drug: Icatibant;   Drug: Placebo
Sponsors:   Jerini AG;   Shire Human Genetic Therapies, Inc.
Recruiting - verified November 2009

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors:   Bayer;   Onyx Pharmaceuticals;   OSI Pharmaceuticals;   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: cryopreservation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Other: biologic sample preservation procedure;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Crohn's Disease
Interventions:   Drug: certolizumab pegol;   Drug: certolizumab pegol
Sponsor:   UCB, Inc.
Recruiting - verified February 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: temozolomide;   Other: placebo
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Autism
Interventions:   Drug: CM-AT;   Drug: Placebo
Sponsor:   Curemark
Recruiting - verified March 2010

Condition:   Diabetic Neuropathies
Interventions:   Drug: Carisbamate 800 mg/d;   Drug: Pregabalin 300 mg/d;   Drug: Placebo;   Drug: Carisbamate 1,200 mg/d
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010

Conditions:   Overactive Bladder;   Neurogenic Detrusor Overactivity
Intervention:   Drug: Fesoterodine
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Conditions:   Breast Neoplasms;   Prostatic Neoplasms
Intervention:   Biological: Anti-NGF AB
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Cetuximab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Gemcitabine;   Drug: Cisplatin
Sponsors:   Accelerated Community Oncology Research Network;   ImClone LLC;   Advanced Clinical Trial Solutions, LLC
Recruiting - verified February 2010

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine;   Drug: vincristine sulfate;   Radiation: fludeoxyglucose F 18
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Stress Disorders, Post-Traumatic
Intervention:   Other: Telemedicine Outreach for PTSD
Sponsor:   Department of Veterans Affairs
Recruiting - verified March 2010

Condition:   Depression
Interventions:   Drug: RO4917523;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: infliximab;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: sham
Sponsor:   Genentech
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Drug: sirolimus;   Drug: tacrolimus;   Drug: vincristine sulfate;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Chronic Schizophrenia
Interventions:   Drug: Lurasidone HCl;   Drug: quetiapine XR
Sponsor:   Dainippon Sumitomo Pharma America
Recruiting - verified February 2010

Condition:   Schizophrenia
Interventions:   Drug: Lurasidone HCl;   Drug: Lurasidone HCl;   Drug: quetiapine XR;   Drug: Placebo
Sponsor:   Dainippon Sumitomo Pharma America
Recruiting - verified February 2010

Conditions:   Advanced Breast Cancer;   Breast Cancer
Interventions:   Drug: Neratinib;   Drug: Lapatinib plus Capecitabine
Sponsor:   Wyeth
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Chemotherapeutic Agent Toxicity;   Fatigue;   Neuropathy;   Neurotoxicity
Interventions:   Dietary Supplement: acetyl-L-carnitine hydrochloride;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: LY450139;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Conditions:   Candidemia;   Candidiasis
Interventions:   Drug: anidulafungin;   Drug: fluconazole
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Biological: panitumumab;   Drug: cisplatin;   Drug: docetaxel;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Major Depressive Disorder (MDD)
Intervention:   Drug: repeat dose
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra];   Drug: Standard anti-rheumatic treatment
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Skin Diseases, Infectious
Interventions:   Drug: Daptomycin;   Drug: Vancomycin, Clindamycin or semi-synthetic Penicillins
Sponsor:   Cubist Pharmaceuticals
Recruiting - verified February 2010

Conditions:   Lumbar Spinal Stenosis;   Neurogenic Intermittent Claudication
Interventions:   Device: Superion™ Interspinous Spacer;   Device: X-STOP® IPD® Device
Sponsor:   VertiFlex, Incorporated
Recruiting - verified February 2010

Condition:   Thromboembolism
Interventions:   Drug: Dabigatran etexilate;   Drug: Warfarin
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Dyslipidemias;   Coronary Heart Disease;   Kidney Disease
Interventions:   Drug: ABT-335;   Drug: Rosuvastatin;   Drug: Placebo
Sponsors:   Abbott;   AstraZeneca
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: midostaurin;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Pancreatic Cancer
Interventions:   Biological: cixutumumab;   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Healthy
Interventions:   Drug: Pregabalin;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Hypoactive Sexual Desire Disorder
Interventions:   Drug: testosterone gel;   Drug: placebo gel
Sponsor:   BioSante Pharmaceuticals
Recruiting - verified February 2010

Condition:   Hypoactive Sexual Desire Disorder
Interventions:   Drug: testosterone gel;   Drug: placebo gel
Sponsor:   BioSante Pharmaceuticals
Recruiting - verified February 2010

Condition:   Epilepsy
Intervention:   Drug: pregabalin
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Prostatic Hyperplasia
Interventions:   Drug: Polyphenon E, 200 mg EGCG bid;   Drug: placebo
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Esophageal Cancer;   Adenocarcinoma of the Esophagus;   Squamous Cell Carcinoma
Interventions:   Drug: OncoGel (Paclitaxel gel);   Drug: cisplatin;   Drug: 5-FU;   Radiation: radiation therapy;   Procedure: esophageal resection
Sponsor:   Protherics
Recruiting - verified March 2010

Condition:   Metastatic Breast Cancer
Interventions:   Drug: docetaxel;   Drug: pertuzumab;   Drug: placebo;   Drug: trastuzumab
Sponsors:   Genentech;   Roche Pharma AG
Recruiting - verified February 2010

Condition:   Osteoarthritis
Interventions:   Drug: SD-6010;   Drug: SD-6010;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Conditions:   Neoplasm Metastasis;   Palliative Care
Interventions:   Drug: Tanezumab 10 mg IV;   Drug: IV Placebo for tanezumab
Sponsor:   Pfizer
Recruiting - verified February 2010

Conditions:   Atherosclerosis;   Myocardial Ischemia;   Myocardial Infarction
Interventions:   Drug: SCH 530348;   Drug: Placebo
Sponsors:   Schering-Plough;   Duke University
Recruiting - verified March 2010

Condition:   Epilepsies, Partial
Interventions:   Drug: pregabalin 600 mg/day;   Drug: pregabalin 150 mg/day
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Sepsis;   Severe Sepsis;   Septic Shock
Interventions:   Procedure: Early Goal Directed Therapy (EGDT);   Procedure: Protocolized Standard Care (PSC);   Procedure: Usual Care (UC)
Sponsors:   National Institute of General Medical Sciences (NIGMS);   University of Pittsburgh
Recruiting - verified September 2008

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2010

Conditions:   Schizophrenia;   Schizophrenic Disorders;   Psychotic Disorders;   Dementia Praecox.
Intervention:   Drug: Paliperidone ER
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Temsirolimus;   Drug: Sorafenib
Sponsor:   Wyeth
Recruiting - verified February 2010

Condition:   Cytomegalovirus Infections
Interventions:   Drug: Placebo;   Drug: Valganciclovir
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009

Condition:   Anemia
Intervention:   Drug: Deferasirox
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Cancer Survivor;   Sexual Dysfunction and Infertility;   Sexuality and Reproductive Issues;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Dietary Supplement: L-arginine/Korean ginseng/ Gingko biloba/damiana-based supplement;   Other: placebo
Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Venous Thrombosis;   Pulmonary Embolism
Interventions:   Drug: Apixaban;   Drug: Enoxaparin
Sponsor:   Bristol-Myers Squibb
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Genetic: chromogenic in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: fluorescent antibody technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: study of socioeconomic and demographic variables;   Procedure: study of high risk factors
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Bladder Cancer
Interventions:   Drug: gemcitabine hydrochloride;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: docetaxel;   Drug: goserelin;   Drug: leuprolide acetate;   Procedure: conventional surgery
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: warfarin;   Drug: apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Benign Prostatic Hyperplasia (BPH)
Intervention:   Device: Prolieve® Thermodilatation System
Sponsor:   Boston Scientific Corporation
Recruiting - verified February 2010

Condition:   Influenza
Intervention:   Drug: oseltamivir (Tamiflu®)
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010

Condition:   Osteoarthritis
Interventions:   Drug: Celecoxib;   Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Cognitive/Functional Effects;   Fatigue;   Metastatic Cancer;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity
Interventions:   Drug: donepezil hydrochloride;   Other: placebo
Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Hot Flashes;   Prostate Cancer
Interventions:   Dietary Supplement: soy isoflavones;   Dietary Supplement: soy protein isolate;   Drug: venlafaxine;   Other: placebo
Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Arthritis, Rheumatoid;   Osteoarthritis
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Fatigue;   Hypothyroidism
Interventions:   Other: physiologic testing;   Procedure: fatigue assessment and management;   Procedure: management of therapy complications
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified November 2009

Condition:   Kidney Cancer
Interventions:   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Southwest Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Fetal Membranes, Premature Rupture
Interventions:   Procedure: Retention of Cerclage;   Procedure: Removal of Cerclage;   Procedure: Removal vs. Retention of Cervical Cerclage
Sponsor:   Obstetrix Medical Group
Recruiting - verified February 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: atrasentan hydrochloride;   Drug: docetaxel;   Drug: prednisone;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: cisplatin;   Drug: etoposide;   Drug: gemcitabine hydrochloride;   Drug: methylprednisolone
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: paclitaxel;   Drug: paclitaxel poliglumex;   Other: clinical observation
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   Southwest Oncology Group
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: zoledronic acid;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group;   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: capecitabine;   Drug: fluorouracil;   Drug: oxaliplatin;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: letrozole;   Other: placebo
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   International Breast Cancer Study Group;   Eastern Cooperative Oncology Group;   Southwest Oncology Group;   Cancer and Leukemia Group B;   European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009

Condition:   Melanoma (Skin)
Interventions:   Biological: recombinant interferon alfa;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   Children's Oncology Group
Recruiting - verified March 2010